12:00 AM
 | 
Aug 20, 2012
 |  BC Week In Review  |  Company News  |  Deals

Ark Therapeutics, Merck KGaA deal

Ark Therapeutics and Merck's EMD Millipore Corp. division signed a non-binding letter of intent to partner for manufacturing of viral-based bioengineered vaccines and live viral...

Read the full 112 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >